Has Gerald Goltz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $44,372 in general payments to Gerald Goltz, MD across 740 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gerald Goltz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gerald Goltz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gerald Goltz, MD

Endocrinology, Diabetes & Metabolism · Sewickley, PANPI 1720033244

Payments from drug & device makers

$44,372in general payments, 2019–2025

Across 740 payments — averaging $59.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$31K
Insulet Corporation$4K
Lilly USA, LLC$2K
Medtronic$2K
Amgen$693
Dexcom, Inc.$603
plus $5K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	266	$31,004
Insulet Corporation	19	$3,766
Lilly USA, LLC	96	$1,866
Medtronic(2 entities)	12	$1,711
Amgen(2 entities)	39	$693
Dexcom, Inc.	49	$603
Bayer	32	$499
Xeris Pharmaceuticals, Inc.	28	$437
Tandem Diabetes Care, Inc.	26	$329
Abbott	11	$279
Sanofi-aventis U.S. LLC	11	$278
AstraZeneca(2 entities)	14	$236
Amneal Pharmaceuticals LLC	10	$211
BD	9	$210
Antares Pharma, Inc.	10	$186
BETA Bionics, Inc.	9	$183
Ascendis Pharma Endocrinology Inc	10	$175
Amphastar Pharmaceuticals, Inc.	8	$159
Boehringer Ingelheim	9	$158
Amarin Pharma, Inc.	8	$147
Embecta Corp.	6	$141
IBSA Pharma Inc.	6	$108
Madrigal Pharmaceuticals	5	$92
Radius Health, Inc.	4	$90
AbbVie	4	$84
Verity Pharmaceuticals Inc.	4	$76
Neurocrine Biosciences, Inc.	3	$72
Corcept Therapeutics	3	$61
Chiesi USA, Inc.	3	$49
Mannkind Corporation	3	$47
Astellas Pharma US Inc	2	$44
Pfizer	2	$42
Esperion Therapeutics, Inc.	2	$39
Halozyme Inc	2	$36
Lifescan, Inc.	1	$33
Currax Pharmaceuticals LLC	2	$30
Johnson & Johnson	2	$28
Averitas Pharma Inc.	1	$27
Merck	2	$26
Valeritas, Inc.	1	$23
Zealand Pharma US, Inc.	1	$19
Cequr Corporation	1	$19
Novartis	1	$16
Azurity Pharmaceuticals, Inc.	1	$16
Sequel Med Tech, LLC	1	$15
Theracosbio, LLC	1	$11

How this compares

$44,372 in reported general payments places this provider in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$124,550

Medicare patients

431

Services billed

1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Sewickley

Mona Al MukaddamPhiladelphia$3.9M
Serge JabbourPhiladelphia$3.1M
Mihaela BiscoveanuPhiladelphia$1.5M
Barbara SimonPhiladelphia$1M
Mitchell LazarPhiladelphia$1M
Vijay BahlPittsburgh$998K
Intekhab AhmedPhiladelphia$926K
Erin KershawPittsburgh$804K
Geraldo SaavedraWhitehall$698K
Arvind CavaleFeasterville Trevose$662K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →